Regeneus Ltd
ASX:RGS
Intrinsic Value
Regeneus Ltd. is regenerative medicine company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of RGS.
Regeneus Ltd's market capitalization is 4.9m AUD.
RGS stock price is 0.008 AUD.
RGS.
RGS. Open DCF Valuation
RGS. Open Relative Valuation
RGS.
RGS's ROE (Return on Equity) has significantly increased in the last 3 years from 236% to 259%.
RGS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 510% to 478%.
RGS has negative Operating Income for the last twelve months.
RGS has negative Net Income for the last twelve months.
RGS's ROE (Return on Equity) for the past 12 months is very high and is equal to 259%.
RGS's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 478%.
RGS has negative Free Cash Flow for the last twelve months.
RGS has negative three-year average ROE (Return on Equity): -129%. The company is not efficient at transforming stockholders' equity into net income.
RGS has negative three-year average ROIC (Return on Invested Capital): -237%. The company is not efficient at using invested capital to generate operating income.
RGS's short-term liabilties (1m AUD) exceed its short-term assets (89k AUD).
RGS's long-term liabilties (1m AUD) exceed its long-term assets (89k AUD).
RGS's D/E (Debt to Equity) is very low and is equal to 0.
RGS's Altman Z-Score is very low and is equal to -715.84.
RGS earns more than enough operating income (-2m AUD) to safely cover interest payments on its debt (-66k AUD).
Fundamental Analysis
Regeneus Ltd
Balance Sheet Decomposition
Regeneus Ltd
| Current Assets | 88.9k |
| Cash & Short-Term Investments | 27.2k |
| Other Current Assets | 61.7k |
| Current Liabilities | 1.2m |
| Accounts Payable | 999.6k |
| Accrued Liabilities | 104k |
| Other Current Liabilities | 81.4k |
Earnings Waterfall
Regeneus Ltd
|
Revenue
|
0
AUD
|
|
Operating Expenses
|
-2m
AUD
|
|
Operating Income
|
-2m
AUD
|
|
Other Expenses
|
-753.9k
AUD
|
|
Net Income
|
-2.8m
AUD
|
Free Cash Flow Analysis
Regeneus Ltd
What is Free Cash Flow?
RGS Profitability Score
Profitability Due Diligence
Regeneus Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Regeneus Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
RGS Solvency Score
Solvency Due Diligence
Regeneus Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Regeneus Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RGS Price Targets Summary
Regeneus Ltd
Shareholder Return
RGS Price
Regeneus Ltd
| Average Annual Return | -16.22% |
| Standard Deviation of Annual Returns | 37.15% |
| Max Drawdown | -99% |
| Market Capitalization | 4.9m AUD |
| Shares Outstanding | 612 874 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Regeneus Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop cell-based therapies. Its therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation. The Company’s platform technologies consist of Progenza and Sygenus. The Progenza is a cellular therapy targeting pain and inflammation, which uses the secretome to improve Mesenchymal Signalling Cells (MSCs).The Progenza repairs local damaged tissue, such as cartilage tissue commonly found in joints like the knees and elbows. The Sygenus is a cell-free topical serum and gel treatment for pain and inflammation derived from Adipose MSCs. The Sygenus consists of selective bioactive molecules from the secretome. The company reduces pain and inflammation, while accelerating tissue healing and repair.
You don't have any saved screeners yet
